ZVRANMSHealthcare·Biotechnology#207 in industry

Zevra Therapeutics, Inc.

Reports in 9d· 2026-05-06

+9.9% · 90d

$9.81

-0.27 (-2.68%)

After-Hours $9.81(+0.00)

News

(2)

April 2026

Apr 20, 20261 week agoDEF 14AHealthcare

ZVRA sells Rare Pediatric Disease Voucher, raising $150 million capital

ZVRAZEVRA THERAPEUTICS, INC.

# 📜 What This Document Is 🗳️ This document is Zevra Therapeutics’ **Proxy Statement** (a detailed legal filing, or Proxy Statement). Think of it as the company's annual "report card" and a voting ballot rolled into one. It is designed to provide shareholders with all the necessary information *be

Read summaryView on SEC EDGAR

Apr 6, 20263 weeks agoPRE 14AHealthcare

ZEVRA THERAPEUTICS, INC. — PRE 14A Filing

ZVRAZEVRA THERAPEUTICS, INC.

# 🧾 What This Document Is This is a **PRE 14A preliminary proxy statement** for Zevra Therapeutics. Think of it as an "invitation and information packet" for the company's 2026 Annual Meeting of Stockholders. It outlines what shareholders will vote on and provides the details they need to make info

Read summaryView on SEC EDGAR

Key Data

Market Cap$579.9M

Open$10.07

Prev Close$10.08

Day Range$9.75 – $10.28

52W Range$7.11 – $13.16

Volume741,765

P/E (TTM)7.27

EPS$1.35

Dividend Yield—

Beta0.89

Profit Margin78.17%

Revenue Growth183.40%

Price Target$22.78(+132.2%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Strong Buy9 analysts

Buy 9Hold 0Sell 0

About

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Healthcare · Biotechnology

61 employees

www.zevra.com